Amelioration of human osteoarthritis symptoms with topical 'biotherapeutics': a phase I human trial.

摘要: Osteoarthritis (OA) treatments presently rely on analgesics, which manage pain but fail to restore imbalances between catabolic and anabolic processes that underlie OA pathogenesis. Recently, biologic (biotherapeutic) drugs, alter the activity of agents such as nitric oxide inflammatory cytokines in ways, allowing tissue regeneration, were evaluated for efficacy treatment. These studies failed demonstrate dramatic abatement symptoms by these suggested strategies might be used treat OA. The present review summarizes current understanding pathogenesis evolving treatments. Preliminary evaluations a novel biotherapeutic strategy are presented here. Twenty patients receiving sour topical cherry seed extract (SCE), an inducer heme oxygenase-1 (HO-1), major physiological protectant against oxidative stress exhibited significantly decreased joint activation CD4+ T cells expressing (p < 0.05), peripheral blood C-reactive protein (CRP), increased leukocyte HO-1 (p < 0.05) comparison with ten placebo-treated patients. SCE inhibits joint-damaging mediator production. This agent therefore meets main criterion classification “biotherapeutic,” or “biologic” agent. negligible toxicity low cost materials make them promising contributors treatment, sustainable within resource limitations wide range